Abstract |
A patient with gastric cancer ( mucinous adenocarcinoma), classified as Borrmann Type 4, refused surgery and a chemotherapy regimen was applied. 5'-DFUR (5'-deoxy-5-fluorouridine) was administered orally at 1,200 mg/day for 23 weeks, for a total dosage of 110.8 g. The patient showed marked remission: the tumor nearly disappeared, distensibility reappeared from the central region of the corpus ventriculi to the incisura angularis, and only small protrusions classified by Yamada's criteria as Type I, remained on the anterior and posterior wall and pars pylorica of the lesser curvature. Side effects were slight anorexia and diarrhea. These could be avoidable by temporal interruption of administration or dosage reduction, to allow long-term treatment. This case can be considered to be one example in which 5'-DFUR proved effective against gastric cancer.
|
Authors | T Koda, T Kurahori, N Iwao, S Sumi, T Sonoda, H Yanagimoto, J Miyaji, N Okahisa |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 14
Issue 8
Pg. 2571-4
(Aug 1987)
ISSN: 0385-0684 [Print] Japan |
PMID | 3039923
(Publication Type: Case Reports, English Abstract, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Floxuridine
- doxifluridine
|
Topics |
- Adenocarcinoma, Mucinous
(drug therapy)
- Antineoplastic Agents
(therapeutic use)
- Female
- Floxuridine
(therapeutic use)
- Humans
- Long-Term Care
- Middle Aged
- Stomach Neoplasms
(drug therapy)
|